Tesamorelin + Ipamorelin

Where the name "Tesamorelin + Ipamorelin" comes from

This is a community and market name. Peptide Health Lab neither coined it nor endorses it, and this page exists only because the name is what people search for.

Who first put these two compounds under one name is not documented in the published literature. A PubMed search for (tesamorelin AND ipamorelin) AND (stack OR "stacking" OR blend OR "combination product" OR compounded) on 1 September 2026 returned 1 record, and that record is a narrative review of performance-enhancing peptides rather than an account of where the pairing came from. What it does document is the surrounding practice: it describes growth hormone-releasing hormone analogues and growth hormone secretagogues as the agents most commonly encountered in online self-administration protocols, and names uncertainty about product composition and about combining practices in unregulated supply as the reason clinicians need a framework at all.^[12] That the practice exists is documented. Who named this particular pair, and on what basis, is not.

One search is reported here as the non-finding it is. A PubMed search for the quoted phrase "tesamorelin-ipamorelin" on 1 September 2026 returned 0 records, with an empty result set and the phrase returned in PubMed's own quoted-phrase-not-found warning; the plain two-term search tesamorelin AND ipamorelin on the same date returned 6. The hyphenated name is a market name, and the indexed literature does not carry it as a phrase.

What's in it and why people combine them

The two components sit at opposite ends of the evidence range, and that is the single most important thing about this page. A 2026 narrative review of peptides modulating the growth hormone axis makes the point structurally: it sorts the compounds people self-administer into tiers running from regulatory-grade randomized trial data at one end to a complete absence of human studies at the other, and tesamorelin and ipamorelin are not in the same tier.^[12]

Tesamorelin is a growth hormone-releasing hormone analogue with real randomized evidence, most of it in one disease. A 2026 meta-analysis of five randomized placebo-controlled trials in adults with HIV found significant reductions in visceral adipose tissue, trunk fat, limb fat, hepatic fat percentage and waist circumference and a significant gain in lean body mass — and, in the same analysis, no significant reduction in subcutaneous adipose tissue and none in body mass index.^[1] The randomized, double-blind, multicentre trial behind the liver result met its primary endpoint of change in hepatic fat fraction over twelve months.^[2]

Ipamorelin is a growth hormone secretagogue with a thin human record. A PubMed search for ipamorelin AND humans[mesh] on 1 September 2026 returned 28 records, 2 of them carrying a randomized-controlled-trial publication type, and reading all 28 on that date found three in which ipamorelin was given to a person. One is a phase 2 randomized placebo-controlled trial in 117 adults having bowel resection, and it did not meet its key efficacy endpoint.^[8] One is a 1999 dose-escalation study in healthy men that built a model of growth hormone release against ipamorelin concentration and reported a single episode of release with a short terminal half-life; it measured a hormone response.^[9] The third is a 2015 anti-doping laboratory study in which ipamorelin was administered nasally to one volunteer so that its urinary metabolites could be characterised for detection purposes; it measured a metabolite, not a clinical outcome.^[6] The rest of that set is assay-development, review, animal and in-vitro work.

The stated reason for putting them together is that one is supposed to raise the amplitude of a growth hormone pulse and the other its frequency. That is a description of two mechanisms sitting next to each other. It is not a result, and no published study has checked whether the two mechanisms do anything together in a person.

Dosing and protocol ranges for either compound live on the individual compound pages, not here. This page carries none.

What the evidence says about the combination

Nothing has been published about the pairing. That is a statement about searches, so here are the searches. A PubMed search for tesamorelin AND ipamorelin on 1 September 2026 returned 6 records. A full-synonym search for (tesamorelin OR TH9507 OR "TH-9507" OR Egrifta) AND ipamorelin on the same date returned the same 6. That synonym set narrowed with (combination OR combined OR "co-administration" OR "co-administered" OR "administered together") returned 1, and a search for tesamorelin AND ipamorelin AND (additive OR additivity OR "add-on" OR adjunct) returned 1.

All six records are 2026 review articles, and none of them administered anything to anybody. One is a structured narrative review of injectable peptides in sports medicine that groups CJC-1295, ipamorelin and tesamorelin together as growth hormone axis agents and concludes that they remain investigational, with uncertain safety profiles and product-quality concerns.^[10] Another is a narrative primer for orthopaedic physicians that lists tesamorelin and "CJC-1295 + ipamorelin" as separate entries in its own key-peptides list and does not pair tesamorelin with ipamorelin anywhere.^[11] A third comes from a different specialty and is the one of the six that states its own method: 106 articles across three databases, prioritizing systematic reviews, meta-analyses and randomized controlled trials. A review that went looking for trial-grade evidence on that scale still had no study of this pairing to report.^[13]

Being named in the same review is not being tested together. The pairing's own claim on this page is graded anecdotal because the searches above returned no study of it — not because the components are weak. One of them is not.

Where the evidence is weak

The approval belongs to one molecule, given one way, in one population, and it does not travel. Tesamorelin's FDA labelling, retrieved from the openFDA drug-label API on 1 September 2026 with an effective date of 29 July 2026, gives the route as subcutaneous injection, and indicates it for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Its own Limitations of Use section states that long-term cardiovascular safety has not been established and that the product is not indicated for weight loss management, having a weight-neutral effect. Those are sentences from the label, not from a paper. An approval held by one component says nothing about the other component, and nothing about the two of them administered together.

Every participant behind the approval had HIV — but the randomized evidence for the molecule does not stop there, and both halves belong on the page. The five trials the 2026 meta-analysis pools were all conducted in adults with HIV on antiretroviral therapy.^[1] A PubMed search for tesamorelin AND (healthy volunteers OR healthy adults) NOT HIV on 1 September 2026 returned 4 records, and all four are human tesamorelin studies outside HIV — which a page asserting "HIV only" would have got wrong. The first is a 20-week randomized double-blind placebo-controlled trial that enrolled 152 adults aged 55 to 87, 66 of them with mild cognitive impairment and the remaining 86 cognitively healthy; 137 completed it, and the completers divide as 76 healthy participants and 61 with mild cognitive impairment. It reported a favourable effect of tesamorelin on cognition in the intention-to-treat analysis at P = .03, comparable in the healthy participants and those with mild cognitive impairment, and it reports the other side too: adverse events in 68 percent of treated participants against 36 percent on placebo, with its authors calling for longer trials rather than claiming a therapeutic result.^[3] The second is a randomized double-blind placebo-controlled substudy of that same trial, in 30 of its participants, which measured brain chemistry rather than body composition: γ-aminobutyric acid rose in all three sampled brain regions at P < .04, with no change observed in glutamate.^[4] The third gave tesamorelin to 13 healthy men, took change in mean overnight growth hormone as its primary endpoint and reported an increase at P = 0.004, while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected.^[5] The fourth is a pharmacokinetic drug-interaction study in healthy volunteers, examining tesamorelin's effect on the pharmacokinetics of simvastatin and ritonavir. Four records, four non-HIV human studies, and not one of them a body-composition outcome trial.

Two randomized trials asked tesamorelin the same cognitive question and disagreed. The 2012 trial in older adults found a favourable cognitive effect. The 2025 phase 2 trial in people with HIV and abdominal obesity took neurocognitive performance as its primary outcome and did not meet it, with a between-group P of .673 and no placebo arm.^[7] Different populations, different designs, opposite answers, and neither one is evidence about a pairing.

A missed primary endpoint is easy to report as a positive page. In that 2025 trial the one result that did reach significance — a median waist circumference difference of -2.7 cm at P = .015 — was a secondary outcome.^[7] A page quoting only the waist figure would be quoting a real number from a trial that missed what it set out to measure.

Ipamorelin's one efficacy trial was negative and is more than a decade old. No significant difference from placebo on the key endpoint, and none on the secondary analyses either.^[8] Nothing since has replaced it. A compound whose only randomized outcome trial was negative is not a compound with weak evidence for a benefit; it is a compound with evidence against one, in the setting that was studied.

Nobody has looked for an interaction. The combination and additivity searches above returned reviews, not experiments. Nothing published describes what a growth hormone-releasing hormone analogue and a secretagogue do to each other's pharmacology, safety profile or hormone response in the same person, and reviews of this class name product composition and quality as unresolved problems on top of that.^[12]

Questions to bring to a provider

The useful conversation is not "is this pairing worth trying". It is "here is what I want changed, and here is what has actually been shown to change it, in whom".

• What is the actual target — visceral fat, a metabolic marker, recovery, something else — and what does standard-of-care evidence offer for that specific thing?
• Tesamorelin's body-composition evidence comes from randomized trials in adults with HIV on antiretroviral therapy.^[1] Its studies outside that population measured cognition, brain chemistry, growth hormone pulsatility and a drug interaction instead. Which body of evidence is the reasoning actually resting on?
• If the reasoning rests on ipamorelin adding something, what does it rest on, given that its only randomized efficacy trial reported no significant difference from placebo?^[8]
• What would a clinician want to monitor in someone raising growth hormone exposure, and what would make them stop?
• Is there a testing obligation in play — a sanctioned sport, a tested employer, a governing body?

Anti-doping status

Both components of this pairing are named individually on the World Anti-Doping Agency Prohibited List in force for 2026, read from the published International Standard PDF on 1 September 2026 by way of the USADA prohibited list page, which returned HTTP 200 with a browser user agent and links the WADA-hosted 2026 PDF, which also returned HTTP 200. This is stated from the document, not from any of the reviews cited above.

• Tesamorelin: section S2.2.4, growth hormone releasing factors. The List names "growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)".
• Ipamorelin: section S2.2.4, growth hormone releasing factors. The same section names "growth hormone secretagogues (GHS) and their mimetics" and gives ipamorelin in its own example list.

Both sit inside S2, Peptide Hormones, Growth Factors, Related Substances, and Mimetics, which the List marks prohibited at all times, in and out of competition, and whose substances it states are non-Specified Substances.

Section S0 does not arise on this page, and it is worth saying why. S0, non-approved substances, reaches a pharmacological substance only when it is not addressed by any of the subsequent sections of the List and has no current approval by any governmental regulatory health authority for human therapeutic use. The first of those two conditions already fails here: both compounds are addressed by a subsequent section, S2.2.4, by name. S0's own trigger is therefore never reached, and no reasoning about either compound's approval status is needed to place it. Where a page has to work out whether an unnamed substance falls under S0, it has to work at it. This one does not.

Tesamorelin's FDA approval does not change its status in sport. An approved drug can be prohibited in competition, and this one is. The approval and the List answer different questions, and a reader who treats the first as an answer to the second has made the error this section exists to prevent.

The review literature covering these compounds does describe them in general terms as carrying widespread anti-doping restrictions, and one 2026 structured narrative review makes those implications part of its stated purpose.^[10] That is a source for what the literature says. It is not a source for what a regulator has done, which is why the two section numbers above were read from the List itself and carry no citation.

Absence from the List is never a statement that a substance is permitted, and the List is reissued annually with sections that renumber between editions. A competing athlete should confirm the current year's list, and their own national anti-doping organization's guidance, rather than this page.